Why QUZYTTIR may be a good option for your patients

QUZYTTIR demonstrated efficacy in improving pruritus in a phase 3 non-inferiority study comparing QUZYTTIR to IV diphenhydramine as an active control.¹

	Shorter mean time in the ED or clinic and lower rates of return visits^1,2
	Less sedation at all assessed time points (1 hour, 2 hours and discharge) in the phase 3 trial^1,2
	Rapid onset with longer duration of action¹

Indication and Usage

QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.
Limitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

Select Safety Information

Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Please see additional Important Safety Information below.

PRICING AGREEMENT NOW AVAILABLE
For information contact your ION Strategic Account Manager

	Request samples through the QUZYTTIR Sample Program to evaluate whether QUZYTTIR may be right for your appropriate patients.
	The QUZYTTIR Assurance Program helps address reimbursement concerns by providing a credit for your practice if your patient's qualified claim is denied.

For an opportunity to trial QUZYTTIR, contact your
local TerSera Specialty Account Manager.

Request a Rep >

For more information about QUZYTTIR, visit QUZYTTIR.com.

Important Safety Information

Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving or operating potentially dangerous machinery. Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

Adverse Reactions: The most common adverse reactions (incidence < 1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.

The most common adverse reactions (incidence ≥2%) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

To report suspected adverse reactions, contact the FDA at 1‍-‍800‍-‍FDA‍-‍1088 or www.FDA.gov‍/‍medwatch. You may also contact TerSera Therapeutics at 1‍-‍844‍-‍334‍-‍4035 or medicalinformation@tersera.com.

Please see Full Prescribing Information.

For cost information for Colorado prescribers, please click here.

References: 1. QUZYTTIR^® (cetirizine hydrochloride injection). Prescribing Information. TerSera Therapeutics LLC. 2. Abella BS, Berger WE, Blaiss MS, et al. Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: a phase III randomized controlled noninferiority trial. Ann Emerg Med. 2020;76(4):489-500.

Sent on behalf of TerSera Therapeutics LLC | 520 Lake Cook Rd, Ste 500 | Deerfield, IL 60015

This content is sponsored by TerSera, and Specialty Practice Network has not independently reviewed or verified the information provided by TerSera.

This email was sent to karleigh.bard-marsh@cencora.com because you have an account with or are a valued partner of Cencora Specialty GPOs | Specialty Practice Network. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.